Acute Liver Failure Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies – Ocera Therapeutics, Akaza Biosciences

Acute Liver Failure Market

DelveInsight has launched a new report on “Acute Liver Failure – Market Insights, Epidemiology, and Market Forecast-2032”.

Some of the key facts of the Acute Liver Failure Market Report:

1. Acute liver failure is a rare clinical syndrome with an annual incidence of fewer than 10 cases per million population in the developed world. In the United States, approximately 2,000 cases of Acute Liver Failure are diagnosed each year (Murali, 2017)
2. In an epidemiological study by Reuben et al., 2016, it was noted that acetaminophen (n-Acetyl-p-Aminophenol) overdose remained the most frequently identified cause of Acute Liver Failure in 16 years study period; the proportion of such patients who enrolled in the registry increased from 31.8% in 1998 to 53.0% in 2013 Hepatitis A virus infection was significantly less evident during the later period [0.8%] than the early period [2.8%]. 

Key benefits of the report:

1. The Acute Liver Failure market report covers a descriptive overview and comprehensive insight of the Acute Liver Failure Epidemiology and Acute Liver Failure  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Acute Liver Failure market report provides insights on the current and emerging therapies.
3. Acute Liver Failure market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Acute Liver Failure market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Liver Failure market.

Got queries? Click here to know more about the Acute Liver Failure Market Landscape.

Acute Liver Failure Overview

Acute liver failure is the development of sudden, severe hepatic dysfunction from an acute insult to the liver, associated with the onset of hepatic encephalopathy and coagulation abnormalities. American Association for the Study of Liver Diseases (AASLD) defines it as the evidence of coagulation abnormality, usually an international normalized ratio above 1.5, and any degree of mental alteration (encephalopathy) in a patient without preexisting liver disease and with an illness of fewer than 26 weeks’ duration.

The condition is categorized into three categories based on the interval between the development of jaundice and the onset of encephalopathy. The first is a hyperacute liver failure in which the onset of encephalopathy is within seven days after the development of jaundice. The second is an acute liver failure in which the onset of encephalopathy is within eight to 28 days after the development of jaundice, and the third is a sub-acute liver failure in which the onset of encephalopathy is in more than 5 weeks but less than 12 weeks after the development of jaundice.

Acute Liver Failure Market 

The dynamics of the Acute Liver Failure market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Ocera Therapeutics, Akaza Biosciences, and others during the forecasted period 2019-2032.

Learn more by requesting for sample @Acute Liver Failure Market Landscape 

Acute Liver Failure Pipeline Therapies and Key Companies 

1. OCR-002: Ocera Therapeutics
2. TAK-242: Akaza Biosciences 

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Acute Liver Failure Patient Share (%) Overview at a Glance

5. Acute Liver Failure Market Overview at a Glance

6. Acute Liver Failure Disease Background and Overview

7. Acute Liver Failure Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Liver Failure 

9. Acute Liver Failure Current Treatment and Medical Practices

10. Unmet Needs

11. Acute Liver Failure Emerging Therapies

12. Acute Liver Failure Market Outlook

13. Country-Wise Acute Liver Failure Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Acute Liver Failure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Acute Liver Failure Market Outlook 2032.

Related Reports:

Acute Liver Failure Pipeline 

Acute Liver Failure Epidemiology

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/